Application of aspidopterys obcordata extract in medicine for preventing and / or treating obesity

Abstract

The invention discloses application of aspidopterys obcordata extract in preparation of a medicine for preventing and / or treating obesity. Experiments prove that the traditional Chinese medicine composition has the effects of remarkably reducing the weight, the in-vivo fat content, the body fat rate and the Lee's index of an obesity model mouse and effectively reducing triglyceride in serum, can be used for treating obesity, particularly treating obesity combined with hypertriglyceridemia, and has a good clinical application prospect.

Description

Technical Field

[0001] The present invention specifically relates to the use of extracts of Aspidopterys obcordata in the preparation of drugs for preventing and / or treating obesity. Background Art

[0002] Obesity refers to excessive accumulation and / or abnormal distribution of body fat, with an increase in body weight, and it is a multi-factorial chronic metabolic disease. With the improvement of material living conditions and the unreasonable diet structure, the incidence of obesity has been increasing year by year. As a systemic endocrine and metabolic disease, obesity not only affects body posture and activities but is also closely related to hyperlipidemia, atherosclerosis, hypertension, coronary heart disease, diabetes, etc. Currently, there are a variety of weight-loss drugs in use and under development. Peripheral-acting weight-loss drugs such as orlistat have various degrees of side effects and application scopes, and blind use should be avoided.

[0003] Aspidopterys obcordata is derived from the dried vine stems of the plant Aspidopterys obcordata Hemsl. var. obcordata of the Malpighiaceae family, and is included in the "Yunnan Chinese Medicinal Materials Standard - Dai Medicine" (2005 edition). The currently clearly defined efficacy and functions are clearing heat and promoting diuresis; expelling wind and dredging collaterals, and it is mainly used for treating heat strangury; stone strangury; rheumatic heat arthralgia. So far, there has been no application research on its treatment of obesity and hypertriglyceridemia. Summary of the Invention

[0004] To solve the above problems, the present invention provides the use of extracts of Aspidopterys obcordata in the preparation of drugs for preventing and / or treating obesity.

[0005] The present invention also provides the use of extracts of Aspidopterys obcordata in the preparation of drugs for preventing and / or treating hypertriglyceridemia.

[0006] The present invention also provides the use of extracts of Aspidopterys obcordata in the preparation of drugs for preventing and / or treating obesity combined with hypertriglyceridemia.

[0007] Furthermore, the extracts of Aspidopterys obcordata are composed of alcohol extracts and water extracts of Aspidopterys obcordata.

[0008] Even further, the extracts of Aspidopterys obcordata are obtained by soaking Aspidopterys obcordata in dilute ethanol, extracting, filtering, drying the filtrate to obtain the alcohol extract; extracting the filter residue with water, filtering, drying the filtrate to obtain the water extract; and mixing and sieving the alcohol extract and the water extract.

[0009] Furthermore, the extract of Aspidopterys obcordata is prepared by soaking Aspidopterys obcordata in 6 - 12 times the volume / weight (v / w), ml / g of dilute ethanol for 0.5 - 1.5 h, then refluxing for 0.5 - 1.5 h, extracting twice in total, filtering, combining the filtrates, and drying the filtrates below 80°C to obtain an ethanol extract; adding 6 - 12 times the volume / weight (v / w), ml / g of water to the filter residue, boiling and extracting for 0.5 - 1.5 h, filtering, and drying the filtrate below 80°C to obtain a water extract; and mixing the ethanol extract and the water extract and passing through an 80 - mesh sieve to obtain the extract.

[0010] Furthermore, every 1 g of the extract of Aspidopterys obcordata contains 6 - 7 g of crude drug, preferably 6.67 g of crude drug per 1 g.

[0011] Further, the drug has the effect of reducing body weight and / or body fat content.

[0012] Further, the drug has the effect of reducing body fat percentage and / or Lee's index.

[0013] Further, the drug has the effect of reducing triglycerides in serum.

[0014] The "dilute ethanol" used in the present invention is an ethanol solution containing C2H5OH of 49.5% - 50.5% (ml / ml) at 20°C.

[0015] The extract of Aspidopterys obcordata, which is a mixture of the dilute ethanol extract and the water extract of Aspidopterys obcordata of the present invention, has been experimentally proven to significantly reduce the body weight, body fat content, body fat percentage and Lee's index of obese model mice, and effectively reduce triglycerides in serum. It can be used for the treatment of obesity, especially for the treatment of obesity complicated with hypertriglyceridemia, and has good clinical application prospects.

[0016] Obviously, based on the above content of the present invention, according to the common general knowledge and conventional means in the art, without departing from the above basic technical idea of the present invention, various other forms of modification, substitution or change can be made.

[0017] The above content of the present invention will be further described in detail below through specific embodiments in the form of examples. However, this should not be construed as limiting the scope of the above subject matter of the present invention to the following examples. All technologies implemented based on the above content of the present invention belong to the scope of the present invention. Specific Embodiments

[0018] Example 1 Preparation of the extract of Aspidopterys obcordata of the present invention

[0019] 1) Take 150 kg of Herba Lycopodii Herba, grind until all of them pass through a 40-mesh sieve, soak the coarse powder of the herbal medicine in dilute ethanol (9 times v / w, ml / g of the herbal medicine) for 1 hour, heat and reflux to extract for 1 hour, and filter; add 9 times v / w, ml / g of the herbal medicine in dilute ethanol to the herbal residue, heat and reflux for 1 hour, filter, combine the dilute ethanol extracts, recover ethanol from the filtrate, and concentrate to a thick paste with a relative density of 1.4 to 1.5 (50° C.), and dry at below 80° C. to obtain a dry extract;

[0020] 2) Take the residue obtained in step 1) and add 9 times the amount of v / w, ml / g water to boil for 1 hour, filter, concentrate the filtrate to a thick paste with a relative density of 1.4-1.5 (50°C), dry it below 80°C to obtain a dry extract, combine it with the dry extract obtained in step 1), grind it, and pass it through an 80-mesh sieve to obtain a Herba Lycopodii Extract (each 1g of Herba Lycopodii Extract is equivalent to 6.67g of crude drug)

[0021] The beneficial effects of the present invention are described below through test examples.

[0022] Test Example 1

[0023] 1. Study on the extraction and preparation technology screening of Dai medicine Herba Cyperi

[0024] According to the previous research results patent CN202110605339.4, i.e. the orthogonal test of dilute ethanol extraction of Psoralea corylifolia, the optimal process parameters for dilute ethanol extraction of Psoralea corylifolia have been obtained, which are a solid-liquid ratio of 1:9, extraction for 1 hour, and 3 extractions in total. In the extraction process of Psoralea corylifolia concentrated pills, the dissolution of effective ingredients (especially water-soluble ingredients) was increased, and the continuous extraction leaching rate determination experiment of Psoralea corylifolia dilute ethanol and water was added in the research of the concentrated pill extraction preparation process.

[0025] Preparation method research: take about 100g of 40-mesh powder of Shieldwing Thunb., weigh accurately, put it in a round-bottom flask, add 900ml of dilute ethanol and put it in the round-bottom flask, plug it and soak it for 1h, connect the reflux device, heat and reflux for 1h, filter it after cooling, and accurately transfer 25ml to 1# evaporating dish (constant weight); add 900ml of dilute ethanol to the residue, heat and reflux for 1h, filter it after cooling, and accurately transfer 25ml to 2# evaporating dish (constant weight); ); add 900ml of dilute ethanol to the residue, heat and reflux for 1h, filter after cooling, accurately transfer 25ml to 3# evaporating dish (constant weight); add 900ml of water to the residue, heat and reflux for 1h, filter after cooling, accurately transfer 25ml to 4# evaporating dish (constant weight), evaporate the above 1#, 2#, 3# and 4# evaporating dishes in a water bath, dry them in an oven at 105℃ for 3h, cool them in a desiccator for 30min, and accurately weigh them respectively. The results are shown in Table 1.

[0026] Table 1 Results of successive extraction of Aspidopterys obcordata with dilute ethanol and water

[0027]

[0028] Based on the above results, the total solid extraction rate after the second and third extractions with dilute ethanol was significantly lower than that of the first extraction. Therefore, considering factors such as the orthogonal test of dilute ethanol extraction, the results of successive extraction with dilute ethanol and water, and the energy consumption and output ratio in large-scale production, the extraction process of concentrated pills of Aspidopterys obcordata was selected as follows: Each batch of 50 kg of Aspidopterys obcordata medicinal materials, a total of three batches of 150 kg, was separately pulverized to all pass through a 40-mesh sieve for standby. The coarse powder of the medicinal materials was added with 9 times the amount of the medicinal materials of dilute ethanol (concentration of 49.5 - 50.5% at 20 °C), soaked for 1 h, then heated under reflux for 1 h and filtered; the residue was added with 9 times the amount of the medicinal materials of dilute ethanol again, heated under reflux for 1 h, filtered, and the dilute ethanol extracts were combined. The filtrate was recovered ethanol and concentrated to a thick paste with a relative density of 1.4 - 1.5 (50 °C), and dried below 80 °C to obtain dry extract; the residue was added with 9 times the amount of water and decocted for 1 h, filtered, the filtrate was concentrated to a thick paste with a relative density of 1.4 - 1.5 (50 °C), and dried below 80 °C to obtain dry extract, which was combined with the above dry extract, pulverized, and passed through an 80-mesh sieve to obtain dry extract powder, and 1 g of extract powder was equivalent to 6.67 g of crude drug.

[0029] The screening of the conditions for making concentrated pills was carried out using a small-scale pill-making machine, and the final pill-making process conditions were determined as follows: 1 kg of extract powder was added with 550 ml of 60% ethanol, mixed evenly and then made into pills. After screening, selecting, drying, packaging, and sterilization, the concentrated pills of Aspidopterys obcordata were obtained.

[0030] II. Pharmacodynamic experiment and result evaluation of concentrated pills of Aspidopterys obcordata in reducing triglyceride in the serum and body fat content in obese model mice

[0031] 2.1 Experimental animals and equipment

[0032] 2.1.1 Experimental animals

[0033] 62 C57BL / 6J mice, SPF grade, male, 6 weeks old. Provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Jing) 2014 - 0004.

[0034] 2.1.2 Feed

[0035] Low-fat feed (D12450 Rodent Diet with 10 kcal% Fat, product batch number: 17100276)

[0036] High-fat feed (D12492 Rodent Diet with 60 kcal% Fat, product batch number:

[0037] 18012208) The above-mentioned feeds were all purchased from Research Diets, Inc. (New Brunswick, NJ, USA).

[0038] The nutritional components of the low-fat feed and high-fat feed are shown in Table 2.

[0039] Table 2 Nutritional components of low-fat feed and high-fat feed

[0040]

[0041]

[0042] 2.1.3 Test drugs

[0043] Concentrated pills of Aspidopterys obcordata Wall. (The pilot-scale product was prepared by Yunnan Institute of Traditional Chinese Medicine and Materia Medica according to the process determined under "I. Screening and Research on the Extraction and Preparation Process of Concentrated Pills of Aspidopterys obcordata Wall.")[[]]END]]

[0044] Orlistat capsules, Chongqing Huasen Pharmaceutical Co., Ltd., batch number: 170303.

[0045] 2.1.4 Reagents

[0046] Triglyceride (TG) assay kit (GPO-PAP method), Mike Biological Co., Ltd., batch number: 091741

[0047] 2.1.5 Experimental instruments and equipment

[0048] SQP electronic balance (Sartorius Scientific Instruments (Beijing) Co., Ltd.);

[0049] Bruker minispec LF90Ⅱ live mouse component analyzer;

[0050] Vernier caliper (Guilin Measuring Tools and Cutting Tools Co., Ltd.);

[0051] 7100 biochemical analyzer (Hitachi, Japan);

[0052] Anke TGL-16B centrifuge.

[0053] 2.1.6 Experimental environment

[0054] IVC independent air supply system of Yunnan Institute of Traditional Chinese Medicine and Materia Medica. Experimental animal use license number: SYXK (Yunnan) K2017-0003, temperature 20-26°C, humidity 40-60%.

[0055] 2.2 Experimental methods

[0056] 2.2.1 Preparation of test substances

[0057] Take the concentrated pills of Aspidopterys obcordata, crush them to pass through an 80-mesh sieve and reserve for use. Take the medicinal powder and prepare a medicinal liquid with purified water at a concentration of 0.094 g of medicinal powder / ml (equivalent to 12.50 g of crude drug / kg) as the test drug.

[0058] 2.2.2 Grouping of experimental animals, administration methods, and administration doses

[0059] Take 62 healthy male C57BL / 6J mice, weighing 18 - 22 g, and randomly divide them into 4 groups, namely: normal control group (14 mice), model control group (16 mice), positive control group (16 mice), and concentrated pill group of Aspidopterys obcordata (16 mice). While the above four groups were fed different diets to establish a model of high-fat obesity in mice, preventive administration was carried out for 7 weeks. The specific methods for model establishment, administration methods, and administration doses are as follows:

[0060] Normal control group: Feed a low-fat diet to establish a model, and intragastrically administer purified water every day during model establishment;

[0061] Model control group: Feed a high-fat diet to establish a model of high-fat obesity in mice, and intragastrically administer purified water every day during model establishment;

[0062] Positive control group: Feed a high-fat diet to establish a model of high-fat obesity in mice, and intragastrically administer orlistat capsules every day during model establishment (the administration dose is 140 mg / kg, which is 3 times the equivalent dose of the clinical human dose for mice);

[0063] Concentrated pill group of Aspidopterys obcordata: Feed a high-fat diet to establish a model of high-fat obesity in mice, and intragastrically administer the concentrated pill liquid of Aspidopterys obcordata every day during model establishment, with an administration dose of 12.50 g of crude drug / kg;

[0064] The intragastric administration volume for each group above is 20 ml / kg. Administer intragastrically once a day. Weigh and record the amount of feed fed every Monday, weigh the remaining feed every Friday, record the food intake of the mice, and the mice drink water voluntarily.

[0065] 2.2.3 Evaluation and detection indicators

[0066] ① Body weight: From week 0 to week 7 of the experiment, measure and record the body weight of each mouse at a fixed time before administration every week;

[0067] ② Body fat content and body fat percentage: From week 0 to week 7 of the experiment, measure the body fat content of each group of mice at a fixed time before administration every week using a Bruker minispec LF90Ⅱ live mouse component analyzer (this instrument can measure the fat content in living small animals multiple times under the conditions of no anesthesia and no trauma for small animals), and calculate the body fat percentage (%) of each mouse according to the body fat percentage calculation formula.

[0068] Body fat percentage (%) = body fat content × 100 / body weight

[0069] ③ Lee's index of mice: After 7 weeks of administration, each group of mice was fasted but given water for 10 - 12 h. After blood collection and sacrificing the mice, the body length of the mice was measured, and the Lee's index was calculated according to the formula.

[0070] Lee's index = (body weight × 10 3 ) 1 / 3 / body length

[0071] ④ Triglyceride: After 7 weeks of administration, each group of mice was fasted but given water for 10 - 12 h. After anesthesia, blood was collected from the femoral artery to detect the content of triglyceride (TG) in the serum.

[0072] 2.3 Experimental results

[0073] 2.3.1 Changes in body weight of mice in each group after administration: See Table 3.

[0074] Table 3 Changes in body weight of experimental mice in each group after administration (x ± s, g)

[0075]

[0076]

[0077] Note: ①. At the 0th week (normal control group n = 14, model control group n = 16, positive control group n = 16, Securidaca inappendiculata group n = 16);

[0078] ②. At the 1st - 7th weeks (normal control group n = 14, model control group n = 16, positive control group n = 15, Securidaca inappendiculata group n = 16), 1 mouse in the positive control group died due to gavage;

[0079] ③. Compared with the normal control group, *P < 0.05, **P < 0.01; compared with the model control group, ▲P < 0.05, ▲▲P < 0.01.

[0080] As can be seen from Table 3: Compared with the normal control group, the body weight of the model control group began to increase significantly since the 4th week, with significant differences at the 4th and 5th weeks (*P < 0.05), and extremely significant differences at the 6th and 7th weeks (**P < 0.01); compared with the model control group, the body weight of the positive control group began to show a trend of slower increase since the 1st week, but there were only significant differences at the 1st, 4th, 6th, and 7th weeks (*P < 0.05); compared with the model control group, the body weight of the Securidaca inappendiculata concentrated pill group began to show a trend of slower increase since the 3rd week, with significant differences at the 3rd and 5th weeks (*P < 0.05), and extremely significant differences at the 4th, 6th, and 7th weeks (**P < 0.01).

[0081] 2.3.2 Changes in body fat content and body fat percentage of mice in each group after administration: See Table 4 and Table 5.

[0082] Table 4 Changes in body fat content of experimental mice in each group after administration (x±s, g)

[0083]

[0084] Note: ①. At the 0th week (normal control group n = 14, model control group n = 16, positive control group n = 16, Securidaca inappendiculata group n = 16);

[0085] ②. At the 1st - 7th weeks (normal control group n = 14, model control group n = 16, positive control group n = 15, Securidaca inappendiculata group n = 16), 1 mouse in the positive control group died due to gavage;

[0086] ③. Compared with the normal control group, *P < 0.05, **P < 0.01; compared with the model control group, ▲P < 0.05, ▲▲P < 0.01.

[0087] Table 5 Changes in body fat percentage of experimental mice in each group after administration (x±s, %)

[0088]

[0089] Note: ①. At the 0th week (normal control group n = 14, model control group n = 16, positive control group n = 16, Securidaca inappendiculata group n = 16);

[0090] ②. At the 1st - 7th weeks (normal control group n = 14, model control group n = 16, positive control group n = 15, Securidaca inappendiculata group n = 16), 1 mouse in the positive control group died due to gavage;

[0091] ③. Compared with the normal control group, *P < 0.05, **P < 0.01; compared with the model control group, ▲P < 0.05, ▲▲P < 0.01.

[0092] As can be seen from Table 4: Compared with the normal control group, the body fat content in the model control group began to increase significantly since the 1st week, with significant differences at the 1st week (*P < 0.05) and extremely significant differences at the 2nd - 7th weeks (**P < 0.01); compared with the model control group, the body fat content in the positive control group showed a trend of slower growth from the 4th - 7th weeks, with significant differences at the 4th - 7th weeks (*P < 0.05); compared with the model control group, the body fat content in the Securidaca inappendiculata concentrated pill group began to show a certain degree of slower growth trend since the 1st week, with extremely significant differences at the 1st week and the 4th - 7th weeks (**P < 0.01).

[0093] As can be seen from Table 5: Compared with the normal control group, the body fat percentage of the model control group began to increase significantly since the 1st week, with a significant difference at the 1st week (*P < 0.05), and extremely significant differences at the 2nd - 7th weeks (**P < 0.01). Considering the changes in body weight, body fat content, and body fat percentage of the mice in the comprehensive model group, after comprehensive consideration, the obesity mouse model was considered successfully established 3 weeks after the start of modeling; compared with the model control group, the body fat percentage of the positive control group showed a trend of slower increase in body fat percentage since the 4th week, but only significant differences were found at the 4th and 7th weeks (*P < 0.05); compared with the model control group, the body fat percentage of the Morinda umbellata L. var. obcordata (Y. Z. Ruan) How ex Hsiao & K. C. Hsia concentrated pill group showed a trend of slower increase since the 3rd week, with significant differences at the 3rd and 5th weeks (*P < 0.05), and extremely significant differences at the 4th, 6th, and 7th weeks (**P < 0.01).

[0094] 2.3.3 Changes in Lee's index of each group of mice after administration: See Table 6.

[0095] Table 6 Changes in Lee's index of experimental mice in each group after administration (x±s)

[0096]

[0097] Note: ①. At the 0th week (normal control group n = 14, model control group n = 16, positive control group n = 16, Morinda umbellata L. var. obcordata (Y. Z. Ruan) How ex Hsiao & K. C. Hsia group n = 16);

[0098] ②. At the 1st - 7th weeks (normal control group n = 14, model control group n = 16, positive control group n = 15, Morinda umbellata L. var. obcordata (Y. Z. Ruan) How ex Hsiao & K. C. Hsia group n = 16), 1 mouse in the positive control group died due to gavage;

[0099] ③. Compared with the normal control group, *P < 0.05, **P < 0.01; compared with the model control group, ▲P < 0.05, ▲▲P < 0.01.

[0100] As can be seen from Table 6: Compared with the normal control group, the Lee's index of the model control group showed an increasing trend, with an extremely significant difference (**P < 0.01); compared with the model control group, the Lee's index of the positive control group showed a decreasing trend, with an extremely significant difference (**P < 0.01); compared with the model control group, the Lee's index of the Morinda umbellata L. var. obcordata (Y. Z. Ruan) How ex Hsiao & K. C. Hsia concentrated pill group showed a decreasing trend, with an extremely significant difference (**P < 0.01).

[0101] 2.3.4 Changes in triglyceride of each group of mice after administration: See Table 7.

[0102] Table 7 Changes in triglyceride of experimental mice in each group after administration (x±s)

[0103]

[0104] Note: ①. In the 0th week (normal control group: n = 14, model control group: n = 16, positive control group: n = 16, Aspidopterys obcordata group: n = 16);

[0105] ②. In the 1st - 7th weeks (normal control group: n = 14, model control group: n = 16, positive control group: n = 15, Aspidopterys obcordata group: n = 16), 1 mouse in the positive control group died due to gavage;

[0106] ③. Compared with the normal control group, *P < 0.05, **P < 0.01; compared with the model control group, ▲P < 0.05, ▲▲P < 0.01.

[0107] As can be seen from Table 7: Compared with the normal control group, the triglyceride level in the model control group showed an increasing trend, and the differences were extremely significant (**P < 0.01); compared with the model control group, the triglyceride level in the positive control group showed an increasing trend, and the differences were extremely significant (**P < 0.01); compared with the model control group, the triglyceride level in the concentrated pill group of Aspidopterys obcordata showed a decreasing trend, and the differences were significant (*P < 0.05).

[0108] 2.4 Experimental conclusions

[0109] The results of this experimental study show that: The concentrated pill of Aspidopterys obcordata has a significant effect on reducing the body weight, body fat content, body fat percentage and Lee's index of obese model mice, and effectively reducing triglyceride in the serum. The main manifestations are as follows:

[0110] ① Body weight: Compared with the model control group, the body weight of the concentrated pill group of Aspidopterys obcordata showed a trend of slower growth since the 3rd week of administration. The differences were significant in the 3rd and 5th weeks (*P < 0.05), and extremely significant in the 4th, 6th and 7th weeks (**P < 0.01);

[0111] ② Body fat content: Compared with the model control group, the body fat content of the concentrated pill group of Aspidopterys obcordata showed a trend of slower growth to a certain extent since the 1st week of administration. The differences were extremely significant in the 1st week and the 4th - 7th weeks (**P < 0.01);

[0112] ③ Body fat percentage: Compared with the model control group, the body fat percentage of the concentrated pill group of Aspidopterys obcordata showed a trend of slower growth since the 3rd week. The differences were significant in the 3rd and 5th weeks (*P < 0.05), and extremely significant in the 4th, 6th and 7th weeks (**P < 0.01);

[0113] ④ Lee's index: Compared with the model control group, the Lee's index in the concentrated pill group of Aspidopterys obcordata showed a decreasing trend, and the difference was extremely significant (**P < 0.01).

[0114] ⑤ Triglyceride: Compared with the model control group, the triglyceride in the concentrated pill group of Aspidopterys obcordata showed a decreasing trend, and the difference was significant (*P < 0.05).

[0115] In summary, the present invention can be used for the treatment of obesity, especially for the treatment of obesity complicated with hypertriglyceridemia, and has good clinical application prospects.

Claims

1. Use of the extract of Aspidopterys obcordata in the preparation of a drug for preventing and / or treating obesity.

2. Use of the extract of Aspidopterys obcordata in the preparation of a drug for preventing and / or treating hypertriglyceridemia.

3. Use of the extract of Aspidopterys obcordata in the preparation of a drug for preventing and / or treating obesity complicated with hypertriglyceridemia.

4. The use according to any one of claims 1 to 3, characterized in that: The extract of Aspidopterys obcordata is composed of an ethanol extract and a water extract of Aspidopterys obcordata.

5. The use according to claim 4, wherein: The extract of Aspidopterys obcordata is obtained by soaking Aspidopterys obcordata in dilute ethanol, extracting, filtering, drying the filtrate to obtain the ethanol extract; extracting the residue with water, filtering, drying the filtrate to obtain the water extract; and mixing and sieving the ethanol extract and the water extract.

6. The use according to claim 5, wherein: The extract of Aspidopterys obcordata is obtained by soaking Aspidopterys obcordata in 6 - 12 times the volume / weight (v / w, ml / g) of dilute ethanol for 0.5 - 1.5 h, then refluxing for 0.5 - 1.5 h, extracting twice in total, filtering, combining the filtrates, drying the filtrates below 80 °C to obtain the ethanol extract; boiling the residue with 6 - 12 times the volume / weight (v / w, ml / g) of water for 0.5 - 1.5 h, filtering, drying the filtrate below 80 °C to obtain the water extract; and mixing and sieving the ethanol extract and the water extract through an 80 - mesh sieve.

7. The use according to claim 6, wherein: The extract of Aspidopterys obcordata contains 6 - 7 g of crude drug per 1 g, preferably 6.67 g of crude drug per 1 g.

8. The use according to claims 1 and 3, characterized in that: The drug has the effect of reducing body weight and / or body fat content.

9. The use according to claim 1 or 3, characterized in that: The drug has the effect of reducing body fat percentage and / or Lee's index.

10. The use according to claim 2 or 3, characterized in that: The drug has the effect of reducing triglycerides in serum.

Images